Discontinued anxiolytic drugs (2009 – 2014)

Bibliography

• Kessler RC, Aguilar-Gaxiola S, Alonso J, et al. The global burden of mental disorders: an update from the WHO World Mental Health (WMH) surveys. Epidemiol Psichiatr Soc 2009;18:23-33
   PubMed Web of Science ®Google Scholar
• Baxter AJ, Vos T, Scott KM, et al. The global burden of anxiety disorders in 2010. Psychol Med 2014;22:1-12
   Google Scholar
• Mandrioli R, Mercolini L, Raggi MA. Benzodiazepine metabolism: an analytical perspective. Curr Drug Metab 2008;9:827-44
   PubMed Web of Science ®Google Scholar
• Rickels K, Schweizer E, Case WG, et al. Long-term therapeutic use of benzodiazepines I. Effects of abrupt discontinuation. Arch Gen Psychiatry 1990;47:899-907
   PubMed Web of Science ®Google Scholar
• Mandrioli R, Mercolini L, Raggi MA. Metabolism of benzodiazepine and non-benzodiazepine anxiolytic-hypnotic drugs: an analytical point of view. Curr Drug Metab 2010;11:815-29
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Eisfeld BS, Dickens SE, et al. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline and venlafaxine. J Clin Psychiatry 2000;61:276-81
   PubMed Web of Science ®Google Scholar
• Mandrioli R, Mercolini L, Saracino MA, Raggi MA. Selective serotonin reuptake inhibitors (SSRIs): therapeutic drug monitoring and pharmacological interactions. Curr Med Chem 2012;19:1846-63
   PubMed Web of Science ®Google Scholar
• Mandrioli R, Mercolini L, Raggi MA. Evaluation of the pharmacokinetics, safety and clinical efficacy of sertraline used to treat social anxiety. Exp Opin Drug Metab Toxicol 2013;9:1495-505
   PubMed Web of Science ®Google Scholar
• Rickels K, Downing R, Schweizer E, Hassman H. Antidepressants for the treatment of generalized anxiety disorder A placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 1993;50:884-95
   PubMed Web of Science ®Google Scholar
• Offidani E, Guidi J, Tomba E, Fava GA. Efficacy and tolerability of benzodiazepines versus antidepressants in anxiety disorders: a systematic review and meta-analysis. Psychother Psychosom 2013;82:355-62
   PubMed Web of Science ®Google Scholar
• Stanley MA, Turner SM. Current status of pharmacological and behavioral treatment of obsessive-compulsive disorder. Behav Ther 1995;26:163-86
   Web of Science ®Google Scholar
• Rickels K, Rynn M. Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry 2002;63:9-16
   PubMed Web of Science ®Google Scholar
• Strawn JR, Geracioti TDJr. The treatment of generalized anxiety disorder with pregabalin, an atypical anxiolytic. Neuropsychiatr Dis Treat 2007;3:237-43
   PubMedGoogle Scholar
• Doble A, Canton T, Dreisler S, et al. RP 59037 and RP 60503: anxiolytic cyclopyrrolone derivatives with low sedative potential interaction with the gamma-aminobutyric acidA/benzodiazepine receptor complex and behavioral effects in the rodent. J Pharmacol Exp Ther 1993;266:1213-26
   PubMed Web of Science ®Google Scholar
• Atack JR. The benzodiazepine binding site of GABA(A) receptors as a target for the development of novel anxiolytics. Expert Opin Investig Drugs 2005;14:601-18
   PubMed Web of Science ®Google Scholar
• Lingford-Hughes A, Wilson SJ, Feeney A, et al. A proof-of-concept study using [11C]flumazenil PET to demonstrate that pagoclone is a partial agonist. Psychopharmacology (Berl) 2005;180:789-91
   PubMed Web of Science ®Google Scholar
• Caveney AF, Giordani B, Haig GM. Preliminary effects of pagoclone, a partial GABAA agonist, on neuropsychological performance. Neuropsychiatr Dis Treat 2008;4:277-82
   PubMedGoogle Scholar
• Atack JR, Pike A, Marshall G, et al. The in vivo properties of pagoclone in rat are most likely mediated by 5’-hydroxy pagoclone. Neuropharmacology 2006;50:677-89
   PubMed Web of Science ®Google Scholar
• De Wit H, Vicini L, Haig GM, et al. Evaluation of the abuse potential of pagoclone, a partial GABAA agonist. J Clin Psychopharmacol 2006;26:268-73
   PubMed Web of Science ®Google Scholar
• Endo Pharmaceuticals Holdings, Inc. US SEC form10-K for the fiscal year ended September 30, 2008. Available from: http://www.wikinvest.com/stock/Indevus_Pharmaceuticals_(IDEV)/Filing/10-K/2008/F2647524 [Last accessed 29 October 2014]
   Google Scholar
• Bateson A. Pagoclone indevus. Curr Opin Investig Drugs 2003;4:91-5
   PubMedGoogle Scholar
• Endo Pharmaceuticals Holdings, Inc. US SEC form10-K for the fiscal year ended September 30, 2005. Available from: http://www.wikinvest.com/stock/Indevus_Pharmaceuticals_(IDEV)/Filing/10-K/2005/F2647750 [Last accessed 29 October 2014]
   Google Scholar
• Fierce Biotech. Indevus announces agreement with teva to develop pagoclone for the treatment of stuttering. Available from: http://www.fiercebiotech.com/press-releases/indevus-announces-agreement-teva-develop-pagoclone-treatment-stuttering [Last accessed 29 October 2014]
   Google Scholar
• Endo Pharmaceuticals Holdings, Inc. US SEC form10-K for the fiscal year ended December 31, 2011. Available from: http://www.sec.gov/Archives/edgar/data/1100962/000119312512089641/d264698d10k.htm [Last accessed 29 October 2014]
   Google Scholar
• Maguire G, Franklin D, Vatakis NG, et al. Exploratory randomized clinical study of pagoclone in persistent developmental stuttering: the examining pagoclone for persistent developmental stuttering study. J Clin Psychopharmacol 2010;30:48-56
   PubMed Web of Science ®Google Scholar
• Ingham RJ. Comments on article by Maguire et al.: pagoclone trial: Questionable findings for stuttering treatment. J Clin Psychopharmacol 2010;30:649-50
   PubMed Web of Science ®Google Scholar
• Maguire GA, Riley GD, Franklin DL. Reply to comments by Dr Ingham Regarding Maguire et al. J Clin Psychopharmacol (2010) 30 (48-56)). J Clin Psychopharmacol 2010;30:650-1
   Web of Science ®Google Scholar
• Sandford JJ, Forshall S, Bell C, et al. Crossover trial of pagoclone and placebo in patients with DSM-IV panic disorder. J Psychopharmacol 2001;15:205-8
   PubMed Web of Science ®Google Scholar
• Buschmann H, Díaz JL, Holenz J, et al. editors. Antidepressants, antipsychotics, and anxiolytics From chemistry and pharmacology to clinical application. Wiley-VCH Verlag GmbH & Co; Weinheim: 2007
   Google Scholar
• The Free Library, PR Newswire Association LLC. Neurogen announces news of NGD 91-1 Phase I-b results, 1995. Available from: http://www.thefreelibrary.com/NEUROGEN+ANNOUNCES+NEWS+OF+NGD+91-1+PHASE+I-B+RESULTS-a016026751 [Last accessed 29 October 2014]
   Google Scholar
• Kamel A, Colizza K, Gunduz M, ET AL. In vitro-in vivo correlation for intrinsic clearance for CP-409,092 and sumatriptan: a case study to predict the in vivo clearance for compounds metabolized by monoamine oxidase. Xenobiotica 2012;42:355-62
   PubMed Web of Science ®Google Scholar
• Sawant AD, Miller EL, Duignan DB, et al. Understanding the clinical pharmacokinetics of a GABAA partial agonist by application of in vitro tools. Xenobiotica 2010;40:476-84
   PubMed Web of Science ®Google Scholar
• Kamel A, Obach RS, Tseng E, Sawant A. Metabolism, pharmacokinetics and excretion of the GABA receptor partial agonist [14C]CP-409,092 in rats. Xenobiotica 2010;40:400-14
   PubMed Web of Science ®Google Scholar
• Atack JR, Wafford KA, Street LJ, et al. MRK-409, a GABAA receptor subtype-selective agonist, is a non-sedating anxiolytic in preclinical species but causes sedation in man. J Psychopharmacol 2011;25:314-28
   PubMed Web of Science ®Google Scholar
• De Haas SL, De Visser SJ, Van Der Post JP, et al. Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABAA alpha2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers. J Psychopharmacol 2008;22:24-32
   PubMed Web of Science ®Google Scholar
• Atack JR. Development of subtype-selective GABAA receptor compounds for the treatment of anxiety, sleep disorders and epilepsy. In: Monti JM, Pandi-Perumal SR, Möhler H, editors. GABA and sleep. Molecular, functional and clinical aspects. Springer Basel; Basel: 2010
   Google Scholar
• Guo J, Davis PC, Gu C, Grimm SW. Absorption, excretion, and metabolism of a potential GABA-A alpha2/3 receptor modulator in rats. Xenobiotica 2011;41:385-99
   PubMed Web of Science ®Google Scholar
• Guo J, Zhang M, Elmore CS, Vishwanathan K. An integrated strategy for in vivo metabolite profiling using high-resolution mass spectrometry based data processing techniques. Anal Chim Acta 2013;780:55-64
   PubMed Web of Science ®Google Scholar
• AstraZeneca. Annual Report, 2010. Available from: http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&blobheader=application%2Fpdf&blobheadername1=Content-Disposition&blobheadername2=MDT-Type&blobheadervalue1=inline%3B+filename%3D2010-Annual-reportpdf&blobheadervalue2=abinary%3B+charset%3DUTF-8&blobkey=id&blobtable=MungoBlobs&blobwhere=1285646055594&ssbinary=true [Last accessed 29 October 2014]
   Google Scholar
• National Institutes of Health, National Center for Advancing Translational Sciences (NCATS), AZD7325. Available from: http://www.ncats.nih.gov/files/AZD7325.pdf [Last accessed 29 October 2014]
   Google Scholar
• AstraZeneca, 20-F form, 2010. Available from: http://online.hemscottir.com/shared/v2/irwizard/sec_item_new.jsp?epic=azn&ipage=6853058&DSEQ=10&SEQ=253&SQDESC=SECTION_PAGE [Last accessed 29 October 2014]
   Google Scholar
• Rinaldi-Carmona M, Congy C, Santucci V, et al. Biochemical and pharmacological properties of SR 46349B, a new potent and selective 5-hydroxytryptamine2 receptor antagonist. J Pharmacol Exp Ther 1992;262:759-68
   PubMed Web of Science ®Google Scholar
• Pehek EA, Nocjar C, Roth BL, et al. Evidence for the preferential involvement of 5-HT2A serotonin receptors in stress- and drug-induced dopamine release in the rat medial prefrontal cortex. Neuropsychopharmacology 2006;31:265-77
   PubMed Web of Science ®Google Scholar
• Scarlota LC, Harvey JA, Aloyo VJ. The role of serotonin-2 (5-HT2) and dopamine receptors in the behavioral actions of the 5-HT2A/2C agonist, DOI, and putative 5-HT2C inverse agonist, SR46349B. Psychopharmacology 2011;213:393-401
   PubMed Web of Science ®Google Scholar
• Sullivan SS, Guilleminault C. Emerging drugs for insomnia: new frontiers for old and novel targets. Expert Opin Emerg Drugs 2009;14:411-22
   PubMed Web of Science ®Google Scholar
• Yadav PN, Kroeze WK, Farrell MS, Roth BL. Antagonist functional selectivity: 5-HT2A serotonin receptor antagonists differentially regulate 5-HT2A receptor protein level in vivo. J Pharmacol Exp Ther 2011;339:99-105
   PubMed Web of Science ®Google Scholar
• Rinaldi-Carmona M, Bouaboula M, Congy C, et al. Up-regulation of 5-HT2 receptors in the rat brain by repeated administration of SR 46349B, a selective 5-HT2 receptor antagonist. Eur J Pharmacol 1993;246:73-80
   PubMed Web of Science ®Google Scholar
• Van Oekelen D, Luyten WH, Leysen JE. 5-HT2A and 5-HT2C receptors and their atypical regulation properties. Life Sci 2003;72:2429-49
   PubMed Web of Science ®Google Scholar
• Jacobs BL, Fornal CA. Activity of brain serotonergic neurons in relation to physiology and behavior. In: Muller CP, Jacobs BL, editors. Handbook of the behavioral neurobiology of serotonin. Elsevier; Amsterdam: 2010
   Google Scholar
• Landolt HP, Meier V, Burgess HJ, et al. Serotonin-2 receptors and human sleep: effect of a selective antagonist on EEG power spectra. Neuropsychopharmacology 1999;21:455-66
   PubMed Web of Science ®Google Scholar
• Drug Development Technology, Osanetant - Novel Investigational Agent for Treatment of Schizophrenia. Available from: http://www.drugdevelopment-technology.com/projects/osanetant/ [Last accessed 29 October 2014]
   Google Scholar
• Sanofi-aventis, Inc. Sanofi-aventis provides an R&D pipeline update, 2009. Available from: http://www.sanofi.no/l/no/no/downloadjsp?file=725EA65C-4959-4C7F-BD15-C9EC17B7FB7C.pdf [Last accessed 29 October 2014]
   Google Scholar
• Sanofi-aventis, Inc. Supplementary financial data for the third quarter of the year ending March 31, 2010. Available from: http://www.ds-pharma.com/ir/library/financial_results_summary/pdf/ebr20100203_2.pdf [Last accessed 29 October 2014]
   Google Scholar
• Sepracor, Inc., 10-K form, 2006. Available from: http://www.wikinvest.com/stock/Sepracor_(SEPR)/Filing/10-K/2007/F6152020 [Last accessed 29 October 2014]
   Google Scholar
• Sepracor, Inc., 8-K form, 2007. Available from: http://www.wikinvest.com/stock/Sepracor_(SEPR)/Filing/8-K/2007/F6151996 [Last accessed 29 October 2014]
   Google Scholar
• Sepracor, Inc. News release, Sepracor, Inc. reports 96% increase in revenue for third quarter and tightens range for full-year 2008 financial guidance, 2008. Available from: http://www.sunovion.com/news/pressReleases/20081028.pdf [Last accessed 29 October 2014]
   Google Scholar
• Dainippon Sumitomo Pharma. Financial results for FY2009, 2010. Available from: http://www.ds-pharma.com/news/pdf/financial2010_05_.pdf [Last accessed 29 October 2014]
   Google Scholar
• Thomas Malloy, Work experience. Available from: http://www.beyond.com/TMalloy-PA [Last accessed 29 October 2014]
   Google Scholar
• English Wikipedia, SEP-227162. Available from: http://en.wikipedia.org/wiki/SEP-227,162 [Last accessed 29 October 2014]
   Google Scholar
• Dainippon Sumitomo Pharma. Notice of Convocation of the 191st Annual Shareholders’ Meeting, 2011. Available from: http://www.ds-pharma.com/ir/shareholder/pdf/191meeting.pdf [Last accessed 29 October 2014]
   Google Scholar
• Dainippon Sumitomo Pharma, About Sunovion Pharmaceuticals, Inc., 2013. Available from: http://www.sunovion.com/news/SunovionCorporateFactSheet11082013.pdf [Last accessed 29 October 2014]
   Google Scholar
• Dainippon Sumitomo Pharma, Third mid-term business plan - FY2013 to FY2017 - Quest for Further Innovation, 2013. Available from: http://www.irwebcasting.com/20130219/8/a1e95a9039/media/20130219_dsp_en_a_01.pdf [Last accessed 29 October 2014]
   Google Scholar
• ClinicalTrials.gov, Trial identifier NCT01774747. A randomized, double-blind, placebo-controlled, multiple ascending oral dose study to evaluate safety, tolerability, and pharmacokinetics of DSP-1053 in healthy subjects and in subjects with major depressive disorder. Available from: http://www.clinicaltrials.gov/ct2/show/record/NCT01774747?term=DSP-1053&rank=1 [Last accessed 29 October 2014]
   Google Scholar
• Cravatt BF, Giang DK, Mayfield SP, et al. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996;84:83-7
   Web of Science ®Google Scholar
• Cravatt BF, Demarest K, Patricelli MP, et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 2001;98:9371-6
   PubMed Web of Science ®Google Scholar
• Lichtman AH, Martin BR. Cannabinoid-induced antinociception is me-diated by a spinal alpha2-noradrenergic mechanism. Brain Res 1991;559:309-14
   PubMed Web of Science ®Google Scholar
• Kathuria S, Gaetani S, Fegley D, et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 2003;9:76-81
   PubMed Web of Science ®Google Scholar
• Gobbi G, Bambico FR, Mangieri R, et al. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci USA 2005;102:18620-5
   PubMed Web of Science ®Google Scholar
• Bátkai S, Pacher P, Osei-Hyiaman D, et al. Endocannabinoids acting at CB1 receptors regulate cardiovascular function in hypertension. Circulation 2004;110:1996-2002
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov, Trial identifier NCT00822744. An eight-week study of SSR411298 as treatment for major depressive disorder in elderly patients (FIDELIO). Available from: http://www.clinicaltrials.gov/ct2/show/NCT00822744?term=SSR-411298&rank=1 [Last accessed 29 October 2014]
   Google Scholar
• Sanofi-aventis, Inc. Press release, Q1 2010: a good first quarter, 2010. Available from: http://www.sanofi.se/l/se/sv/downloadjsp?file=C490F149-1A55-4246-A6E9-C54973E0C7E0.pdf [Last accessed 29 October 2014]
   Google Scholar
• Mantyh PW, Hunt SP, Maggio JE. Substance P receptors: localization by light microscopic autoradiography in rat brain using [3H]SP as the radioligand. Brain Res 1984;307:147
   PubMed Web of Science ®Google Scholar
• Kramer MS, Cutler N, Feighner J, et al. Distinct mechanism for antidepressant activity by blockade of central Substance P receptors. Science 1998;281:1640-5
   PubMed Web of Science ®Google Scholar
• Trist DG, Ratti E, Bye A. Why receptor reserve matters for neurokinin1 (NK1) receptor antagonists. J Recept Signal Transduct Res 2013;33:333-7
   PubMed Web of Science ®Google Scholar
• Pellegatti M, Bordini E, Fizzotti P, et al. Disposition and metabolism of radiolabeled casopitant in humans. Drug Metab Dispos 2009;37:1635-45
   PubMed Web of Science ®Google Scholar
• Schwartz TL, Goradia V. Managing insomnia: an overview of insomnia and pharmacologic treatment strategies in use and on the horizon. Drugs Context 2013;2013:212257
   Google Scholar
• European Medicines Agency press release, GlaxoSmithKline withdraws its marketing authorisation application for Zunrisa (casopitant mesilate), 2009. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2010/01/WC500070023.pdf [Last accessed 29 October 2014]
   Google Scholar
• European Medicines Agency. Questions and answers on the withdrawal of the marketing authorisation application for Zunrisa casopitant, 2009. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2010/01/WC500060223.pdf [Last accessed 29 October 2014]
   Google Scholar
• GSK, Product pipeline, 2014. Available from: http://www.gsk.com/en-gb/research/what-we-are-working-on/product-pipeline/ Last accessed 29 October 2014]
   Google Scholar
• GSK, Clinical Study Register filtered by compound: "casopitant". Available from: http://www.gsk-clinicalstudyregister.com/compounds/casopitant#ps [Last accessed 29 October 2014]
   Google Scholar
• Ratti E, Bellew K, Bettica P, et al. Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder. J Clin Psychopharmacol 2011;31:727-33
   PubMed Web of Science ®Google Scholar
• Khan A, Bhat A, Kolts R, et al. Why has the antidepressant-placebo difference in antidepressant clinical trials diminished over the past three decades? CNS Neurosci Ther 2010;16:217-26
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov, Trial identifier NCT00294346. Safety and efficacy study of AV608 in subjects with social anxiety disorder. Available from: http://clinicaltrials.gov/ct2/show/study/NCT00294346?term=AV608&rank=2 [Last accessed 29 October 2014]
   Google Scholar
• Liebowitz M, Sheehan D, Melia LA, Siffert J. Safety and efficacy of AV608 in subjects with social anxiety disorder. In: Proceedings of the 47th Annual Meeting of the New Clinical Drug Evaluation Unit; Boca Raton (FL); 2007
   Google Scholar
• Novac N. Challenges and opportunities of drug repositioning. Trends Pharmacol Sci 2013;34:267-72
   PubMed Web of Science ®Google Scholar
• Tillisch K, Labus J, Nam B, et al. Neurokinin-1-receptor antagonism decreases anxiety and emotional arousal circuit response to noxious visceral distension in women with irritable bowel syndrome: a pilot study. Aliment Pharmacol Ther 2012;35:360-7
   Google Scholar
• Lippiello PM, Beaver JS, Gatto GJ, et al. TC-5214 (S-(+)-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activity. CNS Neurosci Ther 2008;14:266-77
   PubMed Web of Science ®Google Scholar
• Romanelli M, Gratteri P, Guandalini L, et al. Central nicotinic receptors: structure, function, ligands, and therapeutic potential. ChemMedChem 2007;2:746-67
   PubMed Web of Science ®Google Scholar
• Araki H, Suemaru K, Gomita Y. Neuronal nicotinic receptor and psychiatric disorders: functional and behavioral effects of nicotine. Jpn J Pharmacol 2002;88:133-8
   PubMedGoogle Scholar
• Shytle RD, Silver AA, Lukas RJ. Nicotinic acetylcholine receptors as targets for antidepressants. Mol Psychiatry 2002;7:525-35
   PubMed Web of Science ®Google Scholar
• Picciotto MR, Brunzell DH, Caldarone BJ. Effect of nicotine and nicotinic receptors on anxiety and depression. Neuroreport 2002;13:1097-106
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov, Trial identifier NCT00583544. Available from: https://clinicaltrials.gov/ct2/show/NCT00583544?term=TC-2216&rank=1 [Last accessed 29 October 2014]
   Google Scholar
• Targacept, Inc., 10-K form, 2009. Available from: http://www.getfilings.com/sec-filings/100311/TARGACEPT-INC_10-K/ Last accessed 29 October 2014]
   Google Scholar
• Filliol D, Ghozland S, Chluba J, et al. Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet 2000;25:195-200
   PubMed Web of Science ®Google Scholar
• Chu Sin Chung P, Kieffer BL. Delta opioid receptors in brain function and diseases. Pharmacol Ther 2013;140:112-20
   PubMed Web of Science ®Google Scholar
• Fujii H, Takahashi T, Nagase H. Non-peptidic delta-opioid receptor agonists and antagonists (2000-2012). Exp Opin Ther Pat 2013;23:1181-208
   PubMed Web of Science ®Google Scholar
• Khan A. Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression. Exp Opin Investig Drugs 2009;18:1753-64
   PubMed Web of Science ®Google Scholar
• Hudzik TJ, Maciag C, Smith MA, et al. Preclinical pharmacology of AZD2327: a highly selective agonist of the delta-opioid receptor. J Pharmacol Exp Ther 2011;338:195-204
   PubMed Web of Science ®Google Scholar
• Hudzik TJ, Pietras MR, Caccese R, et al. Effects of the delta opioid agonist AZD2327 upon operant behaviors and assessment of its potential for abuse. Pharmacol Biochem Behav 2014;124:48-57
   PubMed Web of Science ®Google Scholar
• AstraZeneca, Annual Report, 2004. Available from: http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&blobheader=application%2Fpdf&blobheadername1=Content-Disposition&blobheadername2=MDT-Type&blobheadervalue1=inline%3B+filename%3DEnglishpdf&blobheadervalue2=abinary%3B+charset%3DUTF-8&blobkey=id&blobtable=MungoBlobs&blobwhere=1285616438483&ssbinary=true [Last accessed 29 October 2014]
   Google Scholar
• ClinicalTrials.gov, Trial identifier NCT00759395. Study of antidepressant efficacy of a selective, high affinity enkephalinergic agonist in anxious major depressive disorder (AMDD). Available from: http://clinicaltrials.gov/ct2/show/results/NCT00759395?sect=X4301256 [Last accessed 29 October 2014]
   Google Scholar
• Guo J, Gu C, Zhou D, et al. In vitro and in vivo metabolism of a selective delta-opioid receptor. Drug Metab Dispos 2011;39:1883-94
   PubMed Web of Science ®Google Scholar
• Dantzman CL, King MM, Ernst GE, et al. 4-Piperidin-4-ylidenemethyl-benzamides as delta-opioid receptor agonists for CNS indications: identifying clinical candidates. Bioorg Med Chem Lett 2012;22:1174-8
   PubMed Web of Science ®Google Scholar
• Elmore CS, Brush K, Schou M, et al. Synthesis of a delta opioid agonist in [2H6], [2H4], [11C], and [14C] labeled forms. J Label Compd Radiopharm 2011;54:847-54
   Web of Science ®Google Scholar
• ClinicalTrials.gov. Search results for "AZD-7268". Available from: http://www.clinicaltrials.gov/ct2/results?term=AZD-7268&Search=Search [Last accessed 29 October 2014]
   Google Scholar
• National Institutes of Health, National Ceneter for Advancing Translational Sciences (NCATS), AZD7268. Available from: http://www.ncats.nih.gov/files/AZD7268.pdf.pdf [Last accessed 29 October 2014]
   Google Scholar
• ClinicalTrials.gov, Trial identifier NCT01020799. AZD7268 Safety and Tolerability Study. Available from: http://www.clinicaltrials.gov/ct2/show/results/NCT01020799?term=AZD-7268&rank=3 [Last accessed 29 October 2014]
   Google Scholar
• Swanson CJ, Bures M, Johnson MP, et al. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Discov 2005;4:131-44
   PubMed Web of Science ®Google Scholar
• Parsons CG, Danysz W, Hesselink M, et al. Modulation of NMDA receptors by glycine — introduction to some basic aspects and recent developments. Amino Acids 1998;14:207-16
   PubMed Web of Science ®Google Scholar
• Chojnacka-Wojcik E, Tatarczynska E, Pilc A. The anxiolytic-like effect of metabotropic glutamate receptor antagonists after intrahippocampal injection in rats. Eur J Pharmacol 1997;319:153-6
   PubMed Web of Science ®Google Scholar
• Porter RH, Jaeschke G, Spooren W, et al. Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J Pharmacol Exp Ther 2005;315:711-21
   PubMed Web of Science ®Google Scholar
• Zerbib F, Keywood C, Strabach G. Efficacy, tolerability and pharmacokinetics of a modified release formulation of ADX10059, a negative allosteric modulator of metabotropic glutamate receptor 5: an esophageal pH-impedance study in healthy subjects. Neurogastroenterol Motil 2010;22:859-e231
   PubMed Web of Science ®Google Scholar
• Addex press release, Addex’ ADX10059 has potential for Parkinson’s disease levodopa induced dyskinesia (PD-LID), 2009. Available from: http://hugin.info/138017/R/1341036/320635.pdf [Last accessed 29 October 2014]
   Google Scholar
• PR Newswire, Addex reports positive results in Phase IIa clinical trial with ADX10059 in migraine, 2009. Available from: http://www.prnewswire.com/news-releases/addex-reports-positive-results-in-phase-iia-clinical-trial-with-adx10059-in-migraine-58669647.html [Last accessed 29 October 2014]
   Google Scholar
• Addex press release, Development of ADX10059 ended for long-term use, 2009. Available from: http://www.addextherapeutics.com/investors/press-releases/news-details/?tx_ttnews%5Btt_news%5D%20=88&cHash=d075a6fa63acce925582f8f481fb8dc3 [Last accessed 29 October 2014]
   Google Scholar
• Addex, annual report, 2009. Available from: http://www.addextherapeutics.com/fileadmin/user_upload/Annual_Report/2009_Annual_report/Addex_Annual_Report_2009.pdf [Last accessed 29 October 2014]
   Google Scholar
• EU Clinical Trials Register, Trial identifier 2006-003912-23. A Phase IIa, double-blind, placebo-controlled, randomised, parallel-group study, to investigate the safety, tolerability and anxiolytic effect of the mGluR5 negative allosteric modulator ADX10059 in patients with dental anxiety undergoing dental treatment. Available from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-003912-23/GB [Last accessed 29 October 2014]
   Google Scholar
• Fink K, Dooley DJ, Meder WP, et al. Inhibition of neuronal Ca2+ influx by gabapentin and pregablin in the human neocortex. Neuropharmacology 2002;42:229-36
   PubMed Web of Science ®Google Scholar
• Datamonitor Research Store, Pfizer: novel pipeline streamlined post-Wyeth merger, 2009. Available from: http://www.datamonitor.com/store/News/pfizer_novel_pipeline_streamlined_post_wyeth_merger?productid=9DF39DA6-BDBD-4BD5-8620-B848D96166E2 [Last accessed 29 October 2014]
   Google Scholar
• Barratt MJ, Frail DE. Drug repositioning: bringing new life to shelved assets and existing drugs. John Wiley & Sons, Hoboken (NJ); 2012
   Google Scholar
• Pfizer, Inc. Press release, Pfizer discontinues development of two Phase 3 compounds - company to redirect resources to projects considered more likely to bring value to company and patients, 2009. Available from: http://press.pfizer.com/press-release/pfizer-discontinues-development-two-phase-3-compounds [Last accessed 29 October 2014]
   Google Scholar
• ClinicalTrials.gov. Search results for “PD-0332334”. Available from: http://clinicaltrials.gov/ct2/results?term=PD+0332334&Search=Search [Last accessed 29 October 2014]
   Google Scholar
• ClinicalTrials.gov, Trial identifier NCT00735267. A 52-week open-label safety study of PD 0332334 in subjects with generalized anxiety disorder (GAD). Available from: http://clinicaltrials.gov/ct2/show/NCT00735267?term=PD+0332334&rank=13 [Last accessed 29 October 2014]
   Google Scholar
• Alphs L, Benedetti F, Fleischhacker WW, Kane JM. Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it? Int J Neuropsychopharmacol 2012;15:1003-14
   PubMed Web of Science ®Google Scholar
• Price DD, Finniss DG, Benedetti F. A comprehensive review of the placebo effect: recent advances and current thought. Annu Rev Psychol 2008;59:565-90
   PubMed Web of Science ®Google Scholar
• Scannell JW, Blanckley A, Bolden H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov 2012;11:191-200
   PubMed Web of Science ®Google Scholar
• Padhy BM, Gupta YK. Drug repositioning: re-investigating existing drugs for new therapeutic indications. J Postgrad Med 2011;57:153-60
   PubMed Web of Science ®Google Scholar